ArticleBeilstein journal of nanotechnology2026
Protein-based custom-designed molecular nanotraps for biomedical applications.
Article in Beilstein journal of nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of highly selective nanoscaled platforms for molecular recognition has gained significant attention in nanomedicine. Recently, we pioneered a versatile methodology for fabricating custom-designed molecular nanotraps using naturally derived polymers, by relying on protein building blocks and employing the molecular imprinting technique to confer selectivity toward specific molecular targets. With a portfolio of protein-based units that includes cross-linkable silk fibroin and gelatin, the approach enables tailored nanostructures capable of efficient and selective recognition towards molecular targets of clinical relevance. Envisaged applications span from targeting relevant biomarkers for therapeutics, diagnostics, and in situ sensing to building high-complexity order meta-biomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.